Compare ENSG & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENSG | SYRE |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 8.7B |
| IPO Year | 2007 | 2015 |
| Metric | ENSG | SYRE |
|---|---|---|
| Price | $180.84 | $104.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 18 |
| Target Price | ★ $225.80 | $122.53 |
| AVG Volume (30 Days) | 370.9K | ★ 1.0M |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | ★ 14.06 | N/A |
| EPS | ★ 5.11 | N/A |
| Revenue | ★ $5,057,841,000.00 | N/A |
| Revenue This Year | $16.82 | N/A |
| Revenue Next Year | $12.68 | N/A |
| P/E Ratio | $36.85 | ★ N/A |
| Revenue Growth | ★ 18.72 | N/A |
| 52 Week Low | $141.58 | $21.63 |
| 52 Week High | $218.00 | $110.18 |
| Indicator | ENSG | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 52.68 | 63.52 |
| Support Level | $167.76 | $93.45 |
| Resistance Level | $185.69 | $103.16 |
| Average True Range (ATR) | 5.84 | 4.50 |
| MACD | 0.53 | 1.01 |
| Stochastic Oscillator | 56.79 | 99.10 |
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.